27573470|t|Angiopoietin-like protein 4 improves glucose tolerance and insulin resistance but induces liver steatosis in high-fat-diet mice
27573470|a|Angiopoietin-like protein 4 (Angptl4) is a secreted protein predominantly expressed in liver and adipose tissues, and has been identified as an adipokine. Angptl4 is the target gene of peroxisome proliferator‑activated receptors, which are widely used as lipid‑lowering and anti‑diabetic drugs, and previous studies have demonstrated that Angptl4 is able to directly stimulate adipocyte lipolysis. The current study focused on how Angptl4 was involved in regulating lipid and glucose metabolism in high‑fat‑diet (HFD) C57 mice. In the present study, mice were divided into three groups, with standard chow mice as a normal control, adenovirus (adv)‑ injected HFD mice as a model control and adv ‑ Angptl4 ‑ injected HFD mice as the Angptl4+ group. Firstly, compared with the normal control group, mice in the model control group gained more body weight with severe liver steatosis and increased serum levels of triglyceride, total cholesterol, free fatty acids, alanine aminotransferase and aspartate aminotransferase. In the Angptl4+ group, Angptl4 reduced the weight growth rate, aggravated hepatic steatosis and further increased all the aforementioned serum indexes. Secondly, compared with the normal control, the model control group had a reduced glucose tolerance and developed insulin resistance. Angptl4 expression and the phosphorylation levels of several insulin signaling pathway‑associated genes, insulin receptor substrate 1, protein kinase B, janus kinase 2, signal transducer and activator of transcription 3 were downregulated in the liver samples. Adv ‑ Angptl4 injection was observed to improve glucose tolerance and insulin resistance. The genes measured were identified to be upregulated close to normal levels. All the results suggested that Angptl4 served an important role in lipid and glucose metabolism in HFD‑induced obese mice, and this may have a great significance for treatment of hyperlipidemia, diabetes, metabolic syndrome and other diseases.
27573470	0	27	Angiopoietin-like protein 4	T116,T123	C1438918
27573470	28	36	improves	T033	C0184511
27573470	37	54	glucose tolerance	T039	C0178665
27573470	59	77	insulin resistance	T046	C0021655
27573470	82	89	induces	T169	C0205263
27573470	90	105	liver steatosis	T047	C0015695
27573470	109	127	high-fat-diet mice	T015	C0026809
27573470	128	155	Angiopoietin-like protein 4	T116,T123	C1438918
27573470	157	164	Angptl4	T116,T123	C1438918
27573470	171	187	secreted protein	T116,T123	C0033684
27573470	188	201	predominantly	T080	C1542147
27573470	202	211	expressed	T045	C1171362
27573470	215	220	liver	T023	C0736268
27573470	225	240	adipose tissues	T024	C0001527
27573470	255	265	identified	T080	C0205396
27573470	272	281	adipokine	T116,T123	C1955907
27573470	283	290	Angptl4	T028	C1423931
27573470	298	304	target	T169	C1521840
27573470	305	309	gene	T028	C0017337
27573470	313	356	peroxisome proliferator‑activated receptors	T116,T192	C0166418
27573470	383	397	lipid‑lowering	T121	C0003367
27573470	402	421	anti‑diabetic drugs	T121	C1875327
27573470	436	443	studies	T062	C2603343
27573470	467	474	Angptl4	T116,T123	C1438918
27573470	495	504	stimulate	T070	C1948023
27573470	505	514	adipocyte	T025	C0206131
27573470	515	524	lipolysis	T040	C0023796
27573470	538	543	study	T062	C2603343
27573470	559	566	Angptl4	T116,T123	C1438918
27573470	583	599	regulating lipid	T043	C1158445
27573470	604	622	glucose metabolism	T044	C2612213
27573470	626	654	high‑fat‑diet (HFD) C57 mice	T015	C0025929
27573470	671	676	study	T062	C2603343
27573470	678	682	mice	T015	C0025929
27573470	707	713	groups	T078	C0441833
27573470	720	728	standard	T080	C1442989
27573470	729	738	chow mice	T015	C0025929
27573470	744	758	normal control	T096	C0009932
27573470	760	770	adenovirus	T005	C0001483
27573470	772	775	adv	T005	C0001483
27573470	778	795	injected HFD mice	T015	C0025929
27573470	801	814	model control	T096	C0009932
27573470	819	822	adv	T005	C0001483
27573470	825	832	Angptl4	T028	C1423931
27573470	835	852	injected HFD mice	T015	C0025929
27573470	860	874	Angptl4+ group	T078	C0441833
27573470	903	923	normal control group	T096	C0009932
27573470	925	929	mice	T015	C0025929
27573470	937	956	model control group	T096	C0009932
27573470	957	963	gained	T081	C1517378
27573470	964	968	more	T081	C0205172
27573470	969	980	body weight	T032	C0005910
27573470	986	992	severe	T080	C0205082
27573470	993	1008	liver steatosis	T047	C0015695
27573470	1013	1022	increased	T081	C0205217
27573470	1023	1051	serum levels of triglyceride	T034	C1287372
27573470	1053	1070	total cholesterol	T033	C1837784
27573470	1072	1088	free fatty acids	T033	C0236060
27573470	1090	1114	alanine aminotransferase	T033	C0151905
27573470	1119	1145	aspartate aminotransferase	T033	C0151904
27573470	1154	1168	Angptl4+ group	T078	C0441833
27573470	1170	1177	Angptl4	T116,T123	C1438918
27573470	1178	1185	reduced	T080	C0392756
27573470	1190	1208	weight growth rate	T201	C1317142
27573470	1210	1220	aggravated	T080	C1444749
27573470	1221	1238	hepatic steatosis	T047	C0015695
27573470	1251	1260	increased	T081	C0205217
27573470	1284	1289	serum	T031	C0229671
27573470	1290	1297	indexes	T170	C0600653
27573470	1327	1341	normal control	T096	C0009932
27573470	1347	1366	model control group	T096	C0009932
27573470	1373	1398	reduced glucose tolerance	T033	C0151671
27573470	1403	1412	developed	T169	C1527148
27573470	1413	1431	insulin resistance	T046	C0021655
27573470	1433	1440	Angptl4	T116,T123	C1438918
27573470	1441	1451	expression	T045	C1171362
27573470	1460	1475	phosphorylation	T044	C0031715
27573470	1476	1482	levels	T080	C0441889
27573470	1486	1493	several	T081	C0443302
27573470	1494	1530	insulin signaling pathway‑associated	T044	C1512804
27573470	1531	1536	genes	T028	C0017337
27573470	1538	1566	insulin receptor substrate 1	T116,T123	C1505029
27573470	1568	1584	protein kinase B	T116,T126	C1449149
27573470	1586	1600	janus kinase 2	T116,T126	C1527619
27573470	1602	1652	signal transducer and activator of transcription 3	T116,T123	C1530114
27573470	1658	1671	downregulated	T044	C0013081
27573470	1679	1692	liver samples	T024	C0586688
27573470	1694	1697	Adv	T005	C0001483
27573470	1700	1707	Angptl4	T028	C1423931
27573470	1708	1717	injection	T052	C0441655
27573470	1722	1730	observed	T169	C1441672
27573470	1734	1741	improve	T033	C0184511
27573470	1742	1759	glucose tolerance	T039	C0178665
27573470	1764	1782	insulin resistance	T046	C0021655
27573470	1788	1793	genes	T028	C0017337
27573470	1794	1802	measured	T080	C0444706
27573470	1808	1818	identified	T080	C0205396
27573470	1825	1836	upregulated	T044	C0041904
27573470	1846	1852	normal	T080	C0205307
27573470	1853	1859	levels	T080	C0441889
27573470	1869	1876	results	T169	C1274040
27573470	1892	1899	Angptl4	T116,T123	C1438918
27573470	1910	1919	important	T080	C3898777
27573470	1928	1933	lipid	T043	C1158445
27573470	1938	1956	glucose metabolism	T044	C2612213
27573470	1960	1982	HFD‑induced obese mice	T015	C0025933
27573470	2010	2022	significance	T078	C0750502
27573470	2027	2036	treatment	T061	C0087111
27573470	2040	2054	hyperlipidemia	T047	C0020473
27573470	2056	2064	diabetes	T047	C0011847
27573470	2066	2084	metabolic syndrome	T047	C0524620
27573470	2095	2103	diseases	T047	C0012634